Funding (from DOI: 10.1186/s13054-020-02882-x)

Navigation

Article	COVID-19: ICU delirium management during SARS-CoV-2 pandemic
Sections in this Publication
Section	Section 1: Introduction (from DOI: 10.1186/s13054-020-02882-x)
Section	Section 2: COVID-19: Potential factors contributing to ICU delirium (from DOI: 10.1186/s13054-020-02882-x)
Section	Section 3: COVID-19: Neuro-invasive potential of SARS-nCoV-2 as cause of delirium (from DOI: 10.1186/s13054-020-02882-x)
Section	Section 4: COVID-19: ICU delirium management:potential problems and solutions (from DOI: 10.1186/s13054-020-02882-x)
Section	Section 5: Conclusions (from DOI: 10.1186/s13054-020-02882-x)
Section	Authors' contributions (from DOI: 10.1186/s13054-020-02882-x)
Section	Funding (from DOI: 10.1186/s13054-020-02882-x)
Section	Availability of data and materials (from DOI: 10.1186/s13054-020-02882-x)
Section	Ethics approval and consent to participate (from DOI: 10.1186/s13054-020-02882-x)
Section	Consent for publication (from DOI: 10.1186/s13054-020-02882-x)
Section	Competing interests (from DOI: 10.1186/s13054-020-02882-x)
Section	References (from DOI: 10.1186/s13054-020-02882-x)
Named Entities in this Section
Dataset	Pubtator Central BioC-JSON formatted article files

From publication: "COVID-19: ICU delirium management during SARS-CoV-2 pandemic" published as Crit Care; 2020 04 28 ; 24 (1) 176. DOI: https://doi.org/10.1186/s13054-020-02882-x

Funding

JEW is currently receiving grant funding from NCATS (#KL2TR002245) and NIGMS (#R01GM120484). BTP is currently receiving grant funding from NHLBI (#R01HL14678-01). EWE is currently receiving grant funding from NIA (#R01AG058639) and NIGMS (#R01GM120484) serves as a consultant for Pfizer and Eli Lilly. The funding sources had no role in the preparation, review, or approval of the manuscript and decision to submit the manuscript for publication.